Manon Leclerc

2705, Boulevard Laurier, Room T2?05
Quebec, QC G1V4G2, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Distinct alterations of adiponectin, fibroblast growth factor 21 (FGF-21), and insulin-like growth factor binding protein 2 (IGFBP-2) link dysmetabolism with cognitive decline across the Alzheimer's disease spectrum.

Distinct alterations of adiponectin, fibroblast growth factor 21 (FGF-21), and insulin-like growth factor binding protein 2 (IGFBP-2) link dysmetabolism with cognitive decline across the Alzheimer's disease spectrum.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: September 16, 2025

Utility of 18F-FDG PET/CT in the Surveillance of Patients With Neurofibromatosis Type 1.

Utility of 18F-FDG PET/CT in the Surveillance of Patients With Neurofibromatosis Type 1.

Journal: Neurology. Genetics

Published: May 16, 2025

Regional heterogeneity of the blood-brain barrier.

Regional heterogeneity of the blood-brain barrier.

Journal: Nature communications

Published: March 14, 2025

Lower GLUT1 and unchanged MCT1 in Alzheimer's disease cerebrovasculature.

Lower GLUT1 and unchanged MCT1 in Alzheimer's disease cerebrovasculature.

Journal: Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism

Published: March 05, 2024

Cerebrospinal fluid soluble insulin receptor levels in Alzheimer's disease.

Cerebrospinal fluid soluble insulin receptor levels in Alzheimer's disease.

Journal: Alzheimer's & dementia (Amsterdam, Netherlands)

Published: January 23, 2024

High-Fat Diets in Animal Models of Alzheimer's Disease: How Can Eating Too Much Fat Increase Alzheimer's Disease Risk?

High-Fat Diets in Animal Models of Alzheimer's Disease: How Can Eating Too Much Fat Increase Alzheimer's Disease Risk?

Journal: Journal of Alzheimer's disease : JAD

Published: January 13, 2024

Correction to: Higher angiotensin‑converting enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer's disease.

Correction to: Higher angiotensin‑converting enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer's disease.

Journal: Acta neuropathologica communications

Published: November 02, 2023

Higher angiotensin-converting enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer's disease.

Higher angiotensin-converting enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer's disease.

Journal: Acta neuropathologica communications

Published: August 29, 2023

State of the Science on Brain Insulin Resistance and Cognitive Decline Due to Alzheimer's Disease.

State of the Science on Brain Insulin Resistance and Cognitive Decline Due to Alzheimer's Disease.

Journal: Aging and disease

Published: June 02, 2023

Cerebrovascular insulin receptors are defective in Alzheimer's disease.

Cerebrovascular insulin receptors are defective in Alzheimer's disease.

Journal: Brain : a journal of neurology

Published: March 31, 2022

Metabolic determinants of Alzheimer's disease: A focus on thermoregulation.

Metabolic determinants of Alzheimer's disease: A focus on thermoregulation.

Journal: Ageing research reviews

Published: May 17, 2021

Can Natural Products Exert Neuroprotection without Crossing the Blood-Brain Barrier?

Can Natural Products Exert Neuroprotection without Crossing the Blood-Brain Barrier?

Journal: International journal of molecular sciences

Published: February 25, 2021

Showing 1-12 of 15

Last Updated: 09/26/2026